Clinical Trial Update: An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update reports the completion of an open-label Phase I/IIa dose-escalation study of 2B3-101 in patients with solid tumors, including brain m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Lung Cancer
• Malignant Glioma
• Melanoma

Drugs mentioned

• 2B3-101

Snippet

Sponsor: BBB-Therapeutics B.V. | Conditions: Brain Metastases, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED